Cargando…

The anti-angiogenic effect and novel mechanisms of action of Combretastatin A-4

Combretastatin A-4 (CA4) is the lead compound of a relatively new class of vascular disrupting agents that target existing tumor blood vessels. Recent studies showed the CA4 might inhibit angiogenesis. However, the underlying molecular mechanisms by which CA4 exerts its anti-angiogenic effects are n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Min, Huang, Jingjia, Liu, Suyou, Xiao, Yuhang, Qin, Xiyuan, Liu, Jia, Pi, Chaoqiong, Luo, Tiao, Li, Jijia, Chen, Xianghui, Luo, Zhiyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919637/ https://www.ncbi.nlm.nih.gov/pubmed/27338725 http://dx.doi.org/10.1038/srep28139

Ejemplares similares

ZLM-7 exhibits anti-angiogenic effects via impaired endothelial cell function and blockade of VEGF/VEGFR-2 signaling
por: Su, Min, et al.
Publicado: (2016)

Ginsenoside metabolite 20(S)-protopanaxadiol promotes neural stem cell transition from a state of proliferation to differentiation by inducing autophagy and cell cycle arrest
por: Chen, Shali, et al.
Publicado: (2020)

Ginsenoside Rh2 inhibits breast cancer cell growth viaERβ-TNFα pathway: Ginsenoside Rh2 inhibits breast cancer cell growth via ERβ-TNFα
por: Peng, Kunjian, et al.
Publicado: (2022)

Combretastatins: An Overview of Structure, Probable Mechanisms of Action and Potential Applications
por: Karatoprak, Gökçe Şeker, et al.
Publicado: (2020)

Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide
por: Parkins, C S, et al.
Publicado: (2000)

Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown: an exploratory study
por: Gaya, A, et al.
Publicado: (2008)

An Isoxazoloquinone Derivative Inhibits Tumor Growth by Targeting STAT3 and Triggering Its Ubiquitin-Dependent Degradation
por: Xie, Yuanzhu, et al.
Publicado: (2023)

Naturally-occurring spinosyn A and its derivatives function as argininosuccinate synthase activator and tumor inhibitor
por: Zou, Zizheng, et al.
Publicado: (2021)

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
por: Gotink, Kristy J., et al.
Publicado: (2009)

Anti-angiogenic drugs: direct anti-cancer agents with mitochondrial mechanisms of action
por: Quayle, Lewis A., et al.
Publicado: (2017)

Enhancing the anti-angiogenic action of histone deacetylase inhibitors
por: Kuljaca, Selena, et al.
Publicado: (2007)

Transcriptome Analysis of Methyl Jasmonate-Elicited Panax ginseng Adventitious Roots to Discover Putative Ginsenoside Biosynthesis and Transport Genes
por: Cao, Hongzhe, et al.
Publicado: (2015)

Cytotoxicity Studies of Novel Combretastatin and Pterostilbene Derivatives
por: Jakubowska, Joanna, et al.
Publicado: (2014)

Combretastatin-Inspired Heterocycles as Antitubulin Anticancer Agents
por: Hura, Neha, et al.
Publicado: (2018)

Combretastatin A-4 efficiently inhibits angiogenesis and induces neuronal apoptosis in zebrafish
por: Shi, Yun-Wei, et al.
Publicado: (2016)

Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation
por: Kelly, Patrick M., et al.
Publicado: (2017)

Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets
por: Ioannidou, Evangelia, et al.
Publicado: (2021)

Evaluation of the anti-angiogenic action of melatonin in breast cancer
por: Jardim, Bruna V, et al.
Publicado: (2013)

Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma
por: Zhao, Bonan, et al.
Publicado: (2021)

Differential action of pro-angiogenic and anti-angiogenic components of Danhong injection in ischemic vascular disease or tumor models
por: He, Shuang, et al.
Publicado: (2022)

Insights into the angiogenic effects of nanomaterials: mechanisms involved and potential applications
por: Liu, Wenjing, et al.
Publicado: (2020)

Mechanisms of resistance to anti-angiogenic treatments
por: Pezzella, Francesco
Publicado: (2019)

Novel indole-bearing combretastatin analogues as tubulin polymerization inhibitors
por: Kumar, Sunil, et al.
Publicado: (2013)

Combretastatin A4 disodium phosphate-induced myocardial injury
por: Tochinai, Ryota, et al.
Publicado: (2016)

Potent Quinoline-Containing Combretastatin A-4 Analogues: Design, Synthesis, Antiproliferative, and Anti-Tubulin Activity
por: Ibrahim, Tarek S., et al.
Publicado: (2020)

Anti-Angiogenic Effect of Triptolide in Rheumatoid Arthritis by Targeting Angiogenic Cascade
por: Kong, Xiangying, et al.
Publicado: (2013)

Angiogenic signaling pathways and anti-angiogenic therapy for cancer
por: Liu, Zhen-Ling, et al.
Publicado: (2023)

Anti-vascular agent Combretastatin A-4-P modulates Hypoxia Inducible Factor-1 and gene expression
por: Dachs, Gabi U, et al.
Publicado: (2006)

Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue
por: Griggs, J, et al.
Publicado: (2001)

The interaction with tubulin of a series of stilbenes based on combretastatin A-4.
por: Woods, J. A., et al.
Publicado: (1995)

Synthesis and Cytotoxic Activity of a New Group of Heterocyclic Analogues of the Combretastatins
por: Lipeeva, Alla V., et al.
Publicado: (2014)

The protective role of sphingosine-1-phosphate against the action of the vascular disrupting agent combretastatin A-4 3-O-phosphate
por: Shepherd, Joanna, et al.
Publicado: (2017)

Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
por: Haibe, Yolla, et al.
Publicado: (2020)

Ultrasound-promoted two-step synthesis of 3-arylselenylindoles and 3-arylthioindoles as novel combretastatin A-4 analogues
por: Wen, Zhiyong, et al.
Publicado: (2016)

Structurally simplified biphenyl combretastatin A4 derivatives retain in vitro anti-cancer activity dependent on mitotic arrest
por: Tarade, Daniel, et al.
Publicado: (2017)

Anti-angiogenic therapy in ovarian cancer: current situation & prospects
por: Liu, Yinping, et al.
Publicado: (2021)

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
por: Grosios, K, et al.
Publicado: (1999)

Galactose Modified Liposomes for Effective Co-Delivery of Doxorubicin and Combretastatin A4
por: Lian, Bo, et al.
Publicado: (2021)

Combretastatin A4-camptothecin micelles as combination therapy for effective anticancer activity
por: Assali, Mohyeddin, et al.
Publicado: (2019)

Combretastatins D series and analogues: from isolation, synthetic challenges and biological activities
por: de Lima Neto, Jorge, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8h0v3k10rcvq1a67v8d5ods0q6